Did management answer the analysts?
12 analyst questions audited, 4 evaded or deflected.
View Claim Ledger →Bajaj Finserv reported a strong Q3 FY24 with consolidated total income up 34% to INR 29,038 crore and PAT up 21% to INR 2,158 crore.
✓ Verified against BSE filing
Bajaj Finserv reported a strong Q3 FY24 with consolidated total income up 34% to INR 29,038 crore and PAT up 21% to INR 2,158 crore. Growth was driven by robust performance across subsidiaries: Bajaj Finance (AUM +35%, PAT +22%), Bajaj Allianz General Insurance (GDPI +18.7% despite Nat Cat impact), and Bajaj Allianz Life Insurance (IRNB +24%, NBV +19%). The company announced the acquisition of Vidal Healthcare for INR 325 crore to strengthen its healthcare payment ecosystem. Management expressed confidence in sustained growth, citing favorable macro conditions and strategic investments. Key risks include potential regulatory changes on life insurance surrender norms and competitive pressure in motor insurance.
बजाज फिनसर्व ने तीसरी तिमाही में शानदार प्रदर्शन किया। कंपनी की कुल आय 34% बढ़कर 29,038 करोड़ रुपये और मुनाफा 21% बढ़कर 2,158 करोड़ रुपये हुआ। इसकी मुख्य कंपनियों ने अच्छा काम किया - बजाज फाइनेंस का कर्ज पोर्टफोलियो 35% और मुनाफा 22% बढ़ा। बीमा कंपनियों ने भी अच्छी कमाई की। कंपनी ने स्वास्थ्य सेवा के भुगतान को बेहतर बनाने के लिए विडाल हेल्थकेयर को 325 करोड़ रुपये में खरीदा। प्रबंधन का कहना है कि अर्थव्यवस्था मजबूत है और निवेश से आगे भी अच्छा प्रदर्शन होगा। लेकिन बीमा नियमों में बदलाव और मोटर बीमा में प्रतिस्पर्धा से सावधान रहना होगा।
12 analyst questions audited, 4 evaded or deflected.
View Claim Ledger →0 delivered, 0 close, 3 missed.
View Promises →Regulatory risk on life insurance surrender norms
View Risks →Full transcript text is available on this route.
Read Transcript →Total AUM for Bajaj Finance grew 35% year-over-year, driven by strong loan growth and customer acquisition.
Individual rated new business premium grew 24% YoY, highest among top 10 private players.
Excluding natural catastrophe losses, combined ratio improved to 99.5% from 100.3% last year.
Highest ever quarterly customer additions at 38.5 lakh, taking total franchise to 8.04 crore.
Management expects continued strong growth in IRNB, with focus on product mix and channel diversification.
The company aims to grow faster than the industry in profitable segments, leveraging distribution expansion.
The acquisition of Vidal Healthcare will accelerate Finserv Health's position in the healthcare payment spectrum.
Deficiencies pointed out by RBI have been mostly cleared; disbursements expected to resume after regulatory approval.
Due to investments in manpower and rural expansion, combined ratio may temporarily exceed 100% before normalizing.
Management expects NBV growth to sustain as par product mix improves and new bank partnerships contribute.
BFL continues to deliver on AUM growth, profitability, and asset quality targets as per its stated guidance.
Proposed IRDAI changes to surrender values could impact product profitability and persistency.
Motor insurance growth slowed to 5% due to competitive pricing and conservative underwriting stance.
Banks may prioritize deposits over third-party products, pressuring bancassurance growth.
Frequent Nat Cat events increased combined ratio to 102.9% in Q3; core profitability remains strong.
The Gujarat government health scheme may have higher loss ratios due to backlog claims, though 80% is reinsured.
BAGIC's expense ratio may rise as investments in manpower and rural branches continue, impacting near-term profitability.
Analyst raised concern about sustainability of crop and government health business given competitive pricing and tender-based nature.
Higher share of lower-margin products (ULIP, non-par) and investments in new channels may keep VNB margins below prior year levels.
Mentioned in Q1 FY24, Q2 FY24
Management expects NBV growth to sustain as par product mix improves and new bank partnerships contribute.
Mentioned in Q1 FY24, Q2 FY24
Analyst raised concern about sustainability of crop and government health business given competitive pricing and tender-based nature.
Management expects continued strong growth in IRNB, with focus on product mix and channel diversification.
Proposed IRDAI changes to surrender values could impact product profitability and persistency.
View Risks →